Get the Stockscreener App
3.43
2.56%
-0.09
After Hours:
3.43
Ac Immune Sa stock is traded at $3.43, with a volume of 970.38K.
It is down -2.56% in the last 24 hours and up +22.50% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$3.52
Open:
$3.53
24h Volume:
970.38K
Relative Volume:
1.39
Market Cap:
$345.06M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-4.8344
EPS:
-0.7095
Net Cash Flow:
$-68.17M
1W Performance:
+8.89%
1M Performance:
+22.50%
6M Performance:
+65.70%
1Y Performance:
+15.10%
1-Day Range:
$3.405
$3.73
1-Week Range:
$3.09
$3.73
52-Week Range:
$1.4299
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
3.43 | 354.11M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
Why is AC Immune stock up over 23% today? - MSN
Short Interest in AC Immune (NASDAQ:ACIU) Grows By 94.4% - MarketBeat
AC Immune’s Parkinson’s disease candidate shows positive Phase 2 results - MSN
Market Leaders: Will AC Immune SA stock split again soonMarket Trend Review & High Return Stock Watch Alerts - moha.gov.vn
AC Immune (STU:IMR) EV-to-OCF : -3.18 (As of Dec. 24, 2025) - GuruFocus
AC Immune (NASDAQ:ACIU) Trading Up 5%Should You Buy? - MarketBeat
Why ETFs are accumulating AC Immune SA (IMR) stockTechnical Breakout Signals & Free High Impact Stock Picks - bollywoodhelpline.com
Why AC Immune SA stock remains a top recommendationPortfolio Value Report & Real-Time Stock Entry Alerts - Улправда
New Highs: Will AC Immune SA stock recover faster than marketWeekly Investment Summary & Real-Time Volume Trigger Notifications - Улправда
How AC Immune SA stock responds to policy changesPortfolio Return Report & Daily Profit Maximizing Tips - Улправда
Why analysts upgrade AC Immune SA stock2025 Year in Review & AI Enhanced Market Trend Forecasts - Улправда
Will AC Immune SA stock split again soon2025 Risk Factors & High Accuracy Swing Trade Signals - DonanımHaber
Will AC Immune SA (IMR) stock boost dividends further2025 EndofYear Setup & Safe Capital Preservation Plans - DonanımHaber
Should I hold or sell AC Immune SA stock in 2025Market Performance Report & Consistent Income Trade Recommendations - DonanımHaber
Is AC Immune SA stock supported by strong fundamentals2025 Bull vs Bear & Free Community Consensus Stock Picks - Bölüm Sonu Canavarı
Recap Report: Why analysts upgrade AC Immune SA stockWeekly Investment Summary & Growth Oriented Trading Recommendations - ulpravda.ru
Aug Update: Will AC Immune SA stock recover faster than market2025 Market Sentiment & Safe Capital Allocation Plans - Улправда
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD - Seeking Alpha
AC Immune SA (ACIU) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Performance Recap: Will AC Immune SA stock outperform growth indexesJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - moha.gov.vn
Aug Macro: Will AC Immune SA IMR stock outperform value peers2025 Technical Overview & Precise Swing Trade Alerts - moha.gov.vn
AC Immune Perks Up On Positive Parkinson’s Data - Citeline News & Insights
AC Immune reports promising phase 2 results for Parkinson’s therapy - MSN
AC Immune’s Parkinson’s vaccine advances on promising biomarker profile - BioCentury
AC Immune Simulates Curiosity in Neurodegenerative Fight with Global Conference Plans - StocksToTrade
AC Immune (ACIU) Stock: Surges as ACI-7104.056 Shows Potential in Early Parkinson’s Disease - parameter.io
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
Promising Advancements in Parkinson’s Treatment: AC Immune’s ACI-7104 Vaccine Shows Groundbreaking Results - TipRanks
Why Is AC Immune Stock Up Over 23% Today? - Asianet Newsable
AC Immune SA: Navigating Market Momentum - timothysykes.com
ACIU Surges 30% on Positive Parkinson's Therapy Trial Results - GuruFocus
ACIU: ACI-7104.056 shows promise in slowing Parkinson's progression with strong safety and efficacy - TradingView
AC Immune’s Parkinson’s treatment shows promise in slowing disease - Investing.com
AC Immune surges on positive mid-stage trial data for Parkinson’s drug - Seeking Alpha
AC Immune (ACIU) Reports Encouraging Phase 2 Results for Parkins - GuruFocus
Ac Immune shares climb 32.6% premarket after co reports positive trial data for Parkinson's disease therapy - marketscreener.com
AC Immune stock rises after positive Parkinson’s disease trial data - Investing.com India
AC Immune Reports Promising Phase 2 Results for Parkinson’s Therapy - TipRanks
AC Immune’s Parkinson’s treatment shows promise in slowing disease By Investing.com - Investing.com Canada
AC Immune Reports Positive Interim Phase 2 Data for ACI-7104.056 Indicating Potential to Slow Parkinson's Disease Progression - Quiver Quantitative
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease - The Manila Times
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease - GlobeNewswire Inc.
AC Immune SA's (NASDAQ:ACIU) stock price dropped 11% last week; retail investors would not be happy - simplywall.st
Sentiment Watch: Will AC Immune SA stock deliver long term returns - moha.gov.vn
Aug Reactions: Why ETFs are accumulating AC Immune SA IMR stockEarnings Risk Summary & Daily Stock Trend Watchlist - BỘ NỘI VỤ
Quarterly Risk: Why analysts upgrade AC Immune SA stock2025 Sector Review & Fast Momentum Stock Entry Tips - BỘ NỘI VỤ
How AC Immune SA (IMR) stock reacts to weak economyVolume Spike & Weekly High Potential Alerts - Newser
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Is AC Immune SA (IMR) stock a top dividend aristocrat candidate2025 Short Interest & Reliable Price Action Trade Plans - Newser
How big funds are accumulating AC Immune SA (IMR) stock2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Will AC Immune SA (IMR) stock profit from AI boomCPI Data & Comprehensive Market Scan Insights - Newser
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):